W934

W934 is a novel small-molecule inhibitor of the PI3K/Akt signaling pathway, specifically targeting the alpha isoform of phosphoinositide 3-kinase (PI3Kα). Developed by researchers at Zhejiang University, W934 has demonstrated potent in vitro and in vivo antitumor activity against non-small-cell lung cancer (NSCLC) and colorectal cancer models. The compound works by inhibiting PI3Kα kinase activity, thereby suppressing the downstream activation of Akt, leading to G0-G1 cell cycle arrest, inhibition of cell migration and invasion, and the induction of apoptosis. In preclinical studies, oral administration of W934 significantly reduced tumor volume in A549 xenograft mouse models in a dose-dependent manner, positioning it as a potential therapeutic candidate for PI3K-driven malignancies.

Other names

W934W-934W 934